148 results about "Peripheral neuropathy" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The present invention relates to a novel association or combination of active ingredients useful in the prevention and repair of neuronal damage, both centrally and peripherally. In greater detail, the present invention relates to an association or combination of i) an extract of Gastrodia elata and ii) at least one ingredient selected from the group comprising or, alternatively, consisting of citicoline, L-acetylcarnitine and, preferably, at least one vitamin of group D, and / or mixtures thereof, and / or at least one vitamin of group B, and / or mixtures thereof. Furthermore, the invention also relates to the pharmaceutical compositions and / or compositions for medical devices (Regulation (EU) 2017 / 745) and / or nutraceutical and / or food compositions comprising that association and to their use in therapy, in particular in the protection of the functionality of the nervous system and in the prevention and / or treatment of central and peripheral neuropathies.

Provided herein are methods for reducing the likelihood and / or severity of peripheral neuropathy, anemia, and / or neutropenia in an individual being treated with an antibody-drug conjugate (ADC). Also provided herein are methods for increasing dosing amount and / or frequency of an antibody-drug conjugate (ADC) in an individual. In some embodiments, the methods comprise administering to the individual an effective amount of an ADC that comprises an antibody conjugated to a drug moiety via a linker, wherein the antibody comprises a heavy chain comprising a human Fc region with reduced or eliminated effector function. Compositions, uses, and kits related thereto are also provided.

The treatment system includes a limb sleeve containing a heating subsystem, a pressure subsystem, and a vibration subsystem. The heating subsystem provides controlled cyclic heating to the limb, leading to dilation of the microvasculature and improved blood flow to nerve receptors. The pressure subsystem provides progressively staged, cyclic pressure to the limb, thereby improving blood circulation to the limb, reducing edema buildup, and flushing waste out the lymphatic system. The vibration subsystem provides controlled vibrotactile sensation to the limb to promote neuronal stimulation and decrease pain sensation. The treatment system allows for a multi-faceted approach in disease stabilization and assistive, personalized treatment for peripheral neuropathy.

There is provided a transvenous cryoneurolysis system and method for accessing and targeting neural treatment sites to relieve a variety of clinical indications, including peripheral neuropathy. A neurosome approach is described that includes one or more target nerves to receive selective cryoneurolysis via a target vein. The system performs a variety of freeze-thaw cycles via the target vein to induce a desired axial cryolesion along a target nerve. The target nerves and veins are selected to combine the treatment of the identified neurosome for pain relief in addition to the regenerative properties of cryoneurolysis.

Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 domain-containing fragment thereof, or a bclw mimetic. Also provided are exemplary bclw mimetics.

The invention provides an application of gastrodin in preparation of a medicine for treating peripheral neuropathy. According to the application disclosed by the invention, gastrodin can inhibit neuroinflammation mediated by microglia by inhibiting activation of an NF-kB / NLRP3 inflammasome signal channel, so that release of inflammatory factors is reduced, and neuropathy induced by bortezomib is relieved.

The invention provides application of tea catechin in preparation of a medicine for preventing and treating bortezomib-induced peripheral neuropathy. A plurality of in-vitro model results show that tea catechin can be used as a copper death inhibitor, remarkably improves related indexes of bortezomib-induced peripheral neuropathy, improves survival rates of Schwanton cells and SH-SY5Y, improves mitochondrial functions and cell cycle abnormalities of the Schwanton cells, reduces intracellular copper ion, cuprous ion and ATP levels, and can be used for preparing the copper death inhibitor for the peripheral neuropathy of the Bortezomib-induced peripheral neuropathy of the Bortezomib-induced peripheral neuropathy. Meanwhile, the death of Schwann cells and SH-SY5Y induced by the copper death inducer is reduced. In-vivo experiments show that the tea catechin plays a role in protecting functional damage of the bortezomib, and the tea catechin remarkably improves mechanical hyperalgesia, gait abnormality and pathological changes of myelin sheath and axon of mice caused by peripheral neuropathy induced by the bortezomib. The tea catechin can be used as a medicine for peripheral neuropathy induced by bortezomib, and has high clinical application value and development prospect.

The present disclosure relates to compositions for increasing acetylated alpha-tubulin levels in peripheral neuronal cells. The present disclosure also relates to the use of tubulin deacetylase inhibitors, or activators of tubulin acetylation for increasing acetylated tubulin levels in the cells. The present disclosure also relates to methods for assessing risk of developing peripheral neuropathy by assessing the levels of acetylated alpha-tubulin. The present disclosure further relates to methods for treating a subject suffering from a peripheral neuropathy using the compositions described herein.

The application discloses an active polypeptide and application thereof in treating diabetic peripheral neuropathy, and belongs to the technical field of biological polypeptide drugs. An amino acid sequence of the active polypeptide is QVWPDGFVGLAKLWI, which is obtained by step-by-step enzymatic extraction and purification from Morus alba L. which is a homology of medicine and food. The polypeptide can significantly inhibit oxidative stress, inflammatory infiltration and cell apoptosis of Schwann cells induced by a high-sugar environment, and repair the function of damaged nerve cells. Meanwhile, the polypeptide can effectively improve abnormal sciatic nerve conduction function of a diabetic model mouse. The active polypeptide can be used for preparing a drug for treating diabetic peripheral neuropathy, and provides a new candidate drug and research and development direction for the targeted treatment of diabetic peripheral neuropathy.

The invention discloses a traditional Chinese medicine combination effective part capable of improving diabetic peripheral neuropathy. The traditional Chinese medicine combination effective part is prepared from a volatile oil effective part, a water-soluble effective part and an alcohol-soluble effective part, the effective part of the volatile oil comprises alpha-ocimene, alpha-santalene, bisabolol, beta-bisabolol and nerolidol; the water-soluble effective part comprises salvianolic acid A, salvianolic acid B and tanshinol; the alcohol-soluble effective part is prepared from Z-ligustilide, alpha-masticinic acid, beta-masticinic acid, tanshinone IIA, and 2-methoxy-5-acetyl-furangermacane-1 (10)-ene-6-ketone, and the alcohol-soluble effective part is prepared from the following raw materials in parts by weight: 2-methoxy-5-acetyl-furangermacane-1 (10)-ene-6-ketone. The traditional Chinese medicine composition effective part provided by the invention can regulate blood sugar, improve the conduction speed of sciatic nerves, repair damaged tissues, inhibit oxidative stress reaction, resist inflammation and relieve pain, so that the diabetic peripheral neuropathy is improved, the curative effect is reliable, the safety is good, the adverse reaction is low, and the traditional Chinese medicine composition effective part can be used for preparing a medicinal preparation for improving the diabetic peripheral neuropathy.

The invention discloses a nursing test method and system based on surgical glove pressurization, and the method comprises the steps: obtaining a plurality of test groups, each test group comprises a test group and a control group; pressurizing the test group based on a preset nursing mode to obtain test data of different time nodes; on the basis of the same environment, the control group is not subjected to any nursing, and control data of different time nodes are obtained; based on the same test group, performing comparative analysis on the test data and the contrast data of different time nodes to obtain an initial test result of the corresponding test group; traversing all the test groups to obtain an initial test result set, and comparing and analyzing initial test results in the initial test result set to obtain a test result. According to the method, non-drug intervention is adopted, through risk factor evaluation, personnel homogenization training and a surgical glove compression method, the accuracy of peripheral neuropathy testing is improved, and a scientific basis is provided for whether the surgical glove can replace a frozen glove or not.

The invention provides a traditional Chinese medicine preparation for treating peripheral neuropathy caused by chemotherapy, the traditional Chinese medicine preparation comprises an external preparation and an internal preparation, and discloses a preparation method and application of the traditional Chinese medicine preparation. The core pathogenesis of qi and blood stasis and yang deficiency and cold coagulation of the peripheral neuropathy caused by chemotherapy and the characteristic treatment method of tonifying qi and activating blood and warming yang and dredging collaterals are innovatively provided; the composition is rigorous and rigorous, and is clinically safe and effective.

The invention relates to a magnetic pulse treatment device for treating pain. The invention provides breakthrough equipment for patients suffering from foot pain, especially patients suffering from peripheral neuropathy. The main feature of the present invention is that a novel self-aligning applicator is employed to treat the entire foot at the same time without adjustment and sizing. By using segmented solenoids and placing the feet directly in their coherent magnetic core flux, a sufficiently large, sufficiently strong power treatment area can be achieved. The dosage of the whole foot can reach 2500 sigma delta BT within one hour. And the used voltage is extremely low, and the generated heat is extremely little, so that the equipment is suitable for household use.

The invention discloses an application of fenoterol hydrobromide and pharmaceutically acceptable salt thereof in preparation of a medicine for treating diabetic peripheral neuropathy. The fenoterol hydrobromide and the pharmaceutically acceptable salt thereof have obvious effects of promoting growth of peripheral sensory neurite and protecting myelin sheath injury, and can improve symptoms of slow nerve conduction speed and sensory deficiency induced by diabetes mellitus.

The present invention discloses diagnostic and therapeutic markers for diabetic peripheral neuropathy and their applications. The diagnostic and therapeutic marker is eIF6. This invention, for the first time, discovers that upregulation of eIF6 in Schwann cells is closely associated with diabetic peripheral neuropathy. Targeted inhibition of eIF6 can effectively inhibit the progression of neuropathy, which is of great significance for the early diagnosis and treatment of diabetic peripheral neuropathy and for reversing the course of the disease. This invention develops a new method for diagnosing diabetic peripheral neuropathy and a new drug target for treating the disease.

The invention discloses a marker combination, a kit thereof and application of the marker combination to prediction of diabetic peripheral neuropathy, the marker combination comprises human angiotensin (ANG), human vascular endothelial cell adhesion molecule 1 (VCAM1) and human mannan binding lectin serine peptide 1 (MASP1), TMT quantitative proteomics and PRM targeted proteomics are adopted, and the marker combination is used for detecting diabetic peripheral neuropathy. A technology combination strategy of an ELISA experiment is adopted, and key differential expression proteins such as MASP1, VCAM1 and ANG in serum exosomes of patients with diabetic peripheral neuropathy are systematically screened and verified. By establishing a multi-model machine learning diagnosis system based on logistic regression, a support vector machine and a naive Bayes algorithm, simple and rapid identification of diabetic peripheral neuropathy patients is realized, and a new experimental basis is provided for clarification of a molecular regulation network of diabetic peripheral neuropathy; more importantly, a rapid screening tool with clinical application potential is developed.

The invention belongs to the technical field of medical apparatus and instruments, and discloses a household traditional Chinese medicine directional drug permeation device applied to chemotherapy-related peripheral neuropathy, the household traditional Chinese medicine directional drug permeation device comprises an adjustable electrode plate and an elastic bandage, the adjustable electrode plate comprises a main electrode plate and a branch electrode plate detachably mounted at any side position of the main electrode plate; the whole main electrode plate is of an E-shaped structure; square medicine cores are respectively arranged in the three-finger section of the main electrode plate and the rectangular grooves in the bottoms of the branch electrode plates; and elastic bandages cover the front and rear ends of the tops of the main electrode plate and the branch electrode plates. Through improvement and innovation of the shape of the electrode slice, the electrode slice is designed to be of an integrated structure according to the position relation of the eight-wind-eight-evil acupuncture points, the electrode slice is applied to drug penetration treatment of the eight-wind-eight-evil acupuncture points at the tail ends of the four limbs, a personalized treatment scheme can be provided according to the specific conditions of a patient, the treatment accuracy and effectiveness are enhanced, and the treatment cost is reduced. And a new normal form for treating the chemotherapy-related peripheral neuropathy is created.

The invention discloses a traditional Chinese medicine composition for treating diabetic peripheral neuropathy. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-40 parts of astragalus membranaceus, 10-20 parts of angelica sinensis, 8-15 parts of cassia twig, 8-15 parts of red paeony root, 15-30 parts of caulis spatholobi, 5-10 parts of tetrapanax papyriferus, 3-6 parts of scorpio and 1-3 parts of centipede.

The invention relates to the field of medical instruments, and discloses a diabetic peripheral neuropathy examination device which comprises a tuning fork part and an examination hammer part, the tuning fork part comprises a fork handle and two fork arms arranged on the fork handle, the examination hammer comprises a hammer rod part and two hammer head blocks detachably connected with the hammer rod part, and the two hammer head blocks are slidably arranged on the two fork arms respectively. And locking pieces are arranged on the hammer blocks. The invention provides a peripheral neuropathy examination tool which is convenient to carry.

The application discloses application of arctigenin derivative or a pharmaceutically acceptable salt thereof in preparation of a medicament for treating peripheral neuropathy in diabetes. The application shows through a large number of experiments that the arctigenin derivative and the pharmaceutically acceptable salt thereof can obviously improve nerve conduction velocity and sensory loss symptoms of diabetic mice, thereby achieving the effect of treating peripheral neuropathy.

The application relates to a pharmaceutical application technology, in particular to application of gallic acid in preparation of a medicine for preventing or treating peripheral neuropathy. The peripheral neuropathy is acute peripheral neuropathy caused by using a chemotherapy drug, oxaliplatin. The gallic acid has a protective effect on acute peripheral nerve toxicity of mice induced by oxaliplatin. The medicine, gallic acid, can be used as an adjuvant of a chemotherapy drug for cancer treatment, and has a significant alleviating effect on nerve toxicity caused by chemotherapy.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies including grade IV glioblastoma with native IDH, grade 3 glioma, embryonal tumour, pituitary tumour, meningioma, haemangiopericytoma, haemangioblastoma, mesothelioma, bile duct adenocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urachal cancer, adenocarcinoma of the bladder and oesophageal cancer, and for the treatment of neuropathic pain caused by diabetic peripheral neuropathy, spinal cord injury, post-herpetic neuralgia, chemotherapeutic agent, antitumour agent, cancer, fibromyalgia or hepatitis. The present invention also relates to the pharmaceutical composition comprising 2-hydroxy-octadecene-9-cis-oate.

The present invention provides a pharmaceutical composition for treating an acute-phase peripheral neuropathy induced by a chemotherapeutic agent, the pharmaceutical composition comprising an alkalizing agent. By administering this pharmaceutical composition, it is possible to treat an acute-phase peripheral neuropathy induced by a chemotherapeutic agent, in particular, a chemotherapeutic agent for cancer. The present invention also provides an anticancer pharmaceutical composition that contains an alkalizing agent and a chemotherapeutic agent for cancer and that is designed to suppress an acute-phase peripheral neuropathy induced by the chemotherapeutic agent or to suppress worsening of symptoms caused by the peripheral neuropathy. By administering this pharmaceutical composition, it is possible to provide a cancer treatment in which an acute-phase peripheral neuropathy or worsening of symptoms caused by the peripheral neuropathy is suppressed.

The invention relates to the technical field of biological medicines, in particular to a hydroxyl-alpha-sanshool gel plaster, a preparation method thereof and application of the hydroxyl-alpha-sanshool gel plaster in preparation of a medicine for treating peripheral neuropathic pain. The preparation method specifically comprises the following steps: (1) mixing hydroxyl-alpha-sanshool with hydroxypropyl-beta-cyclodextrin for reaction, and removing a solvent to obtain a reactant; (2) filtering a reactant, and freeze-drying the reactant to obtain a hydroxyl-alpha-sanshool cyclodextrin inclusion compound; and (3) preparing the hydroxyl-alpha-sanshool cyclodextrin inclusion compound into the hydroxyl-alpha-sanshool gel plaster. The invention aims to construct a hydroxypropyl-beta-cyclodextrin inclusion compound system through a molecular inclusion technology so as to improve the water solubility of HAS and increase the stability of HAS. The prepared gel plaster is used for local treatment of peripheral nerve pathological pain, and aims to avoid loss caused by a first-pass effect, improve patient discomfort caused by frequent administration and reduce side effects caused by systemic administration.

The present invention relates to a multilayer pharmaceutical or nutraceutical solid dosage form comprising at least one pyrimidine derivative, purine derivative or any salt or solvate thereof and least one B-group vitamin. It also provides three methods for producing said multilayer pharmaceutical or nutraceutical solid dosage forms. Furthermore, the present invention is also related to therapeutic uses of said multilayer pharmaceutical or nutraceutical solid dosage forms, particularly for the treatment and / or prevention of peripheral neuropathy.

The invention belongs to the technical field of biomedical detection, and discloses a biomarker for predicting or diagnosing diabetic peripheral neuropathy and application of the biomarker, and the biomarker comprises GREM2 and HPD. The biomarker disclosed by the invention is high in sensitivity, strong in specificity, capable of accurately identifying DPN and reliable in detection result, the AUC value of combined diagnosis of two differential proteins reaches 0.86, and the biomarker is remarkably superior to an existing clinical marker. When the biomarker is combined with clinical markers Age, BMI, T2DM daughter and HbA1c for use, the AUC value of the biomarker can reach 0.95. When the biomarker is applied, only a small number of blood samples of a patient are needed, the detection method is simple, convenient and rapid, the professional requirement is not high, and the biomarker is suitable for clinical popularization.

A method of treating or preventing peripheral neuropathies includes administering a therapeutically effective amount of a cyclic amine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof to a patient who needs treatmentwherein, carbon marked with * is asymmetric carbon; and A represents a group represented by general formulae (IIa), (IIb) or (IIc):wherein R1 represents a methyl group or an ethyl group optionally substituted with a halogen atom, R2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms, each R3 independently represents a methyl group or an ethyl group, and n represents 1 or 2.

The invention provides application of ursodesoxycholic acid in preparation of a medicine for treating peripheral neuropathy. The ursodesoxycholic acid provided by the invention can promote the recovery of sciatic nerve function indexes after the sciatic nerve of a mouse is cut off, and improve the electroneurographic signal conduction function of an injured part; meanwhile, the UDCA can also relieve oxaliplatin-induced ischiadic nerve signal transduction disorder of mice and related crymodynia sensitive symptoms. In addition, the invention further reveals that the relieving effect of the UDCA on the peripheral neuropathy does not depend on promoting Schwann cell migration. According to the discovery, the application value of the UDCA in treating peripheral neuropathy caused by multiple factors is expanded, and a new strategy is provided for clinical treatment of the UDCA.